DE10251170A1 - Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel - Google Patents

Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel Download PDF

Info

Publication number
DE10251170A1
DE10251170A1 DE10251170A DE10251170A DE10251170A1 DE 10251170 A1 DE10251170 A1 DE 10251170A1 DE 10251170 A DE10251170 A DE 10251170A DE 10251170 A DE10251170 A DE 10251170A DE 10251170 A1 DE10251170 A1 DE 10251170A1
Authority
DE
Germany
Prior art keywords
hydrogen
alkyl
group
aryl
radical selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10251170A
Other languages
German (de)
English (en)
Inventor
Thomas Trieselmann
Bradford S. Hamilton
Dirk Stenkamp
Stephan Georg Müller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE10251170A priority Critical patent/DE10251170A1/de
Priority to US10/695,077 priority patent/US20040127733A1/en
Priority to AU2003278157A priority patent/AU2003278157A1/en
Priority to JP2004547613A priority patent/JP2006508090A/ja
Priority to PCT/EP2003/012049 priority patent/WO2004039784A1/de
Priority to EP03769472A priority patent/EP1558583A1/de
Priority to CA002504213A priority patent/CA2504213A1/en
Publication of DE10251170A1 publication Critical patent/DE10251170A1/de
Priority to US11/276,649 priority patent/US7214698B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE10251170A 2002-10-31 2002-10-31 Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel Withdrawn DE10251170A1 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE10251170A DE10251170A1 (de) 2002-10-31 2002-10-31 Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US10/695,077 US20040127733A1 (en) 2002-10-31 2003-10-28 New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
AU2003278157A AU2003278157A1 (en) 2002-10-31 2003-10-30 Novel phenylethanolamine derivatives and the use of the same as beta-3-agonists
JP2004547613A JP2006508090A (ja) 2002-10-31 2003-10-30 新規β−アゴニスト、それらの製造方法及び医薬組成物としてのそれらの使用
PCT/EP2003/012049 WO2004039784A1 (de) 2002-10-31 2003-10-30 Neue phenylethanolaminderivate und deren verwendung als beta-3-agonisten
EP03769472A EP1558583A1 (de) 2002-10-31 2003-10-30 Neue phenylethanolaminderivate und deren verwendung als beta-3-agonisten
CA002504213A CA2504213A1 (en) 2002-10-31 2003-10-30 New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
US11/276,649 US7214698B2 (en) 2002-10-31 2006-03-09 Beta-agonists, processes for preparing them and their use as pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10251170A DE10251170A1 (de) 2002-10-31 2002-10-31 Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
DE10251170A1 true DE10251170A1 (de) 2004-05-13

Family

ID=32103286

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10251170A Withdrawn DE10251170A1 (de) 2002-10-31 2002-10-31 Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Country Status (6)

Country Link
EP (1) EP1558583A1 (enrdf_load_stackoverflow)
JP (1) JP2006508090A (enrdf_load_stackoverflow)
AU (1) AU2003278157A1 (enrdf_load_stackoverflow)
CA (1) CA2504213A1 (enrdf_load_stackoverflow)
DE (1) DE10251170A1 (enrdf_load_stackoverflow)
WO (1) WO2004039784A1 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042679A1 (de) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4916317B2 (ja) * 2004-02-14 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規持続作用性β−２−アゴニスト及び薬剤としてのその使用
US7405232B2 (en) 2004-02-14 2008-07-29 Boehringer Ingelheim International Gmbh Long acting beta-2 agonists and their use as medicaments
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005052101A1 (de) * 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005052103A1 (de) * 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005052102A1 (de) * 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005052127A1 (de) * 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue indol-haltige Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US20090221589A1 (en) * 2005-12-19 2009-09-03 Thomas Trieselmann Use of aminoalcohol derivatives for the treatment of overactive bladder
GB0705400D0 (en) * 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
WO2008132162A1 (en) * 2007-04-26 2008-11-06 Boehringer Ingelheim International Gmbh 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
LT3262028T (lt) 2014-12-17 2022-01-10 Pimco 2664 Limited N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamido ir n-(-4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamido junginiai ir jų terapinis panaudojimas
GB202304652D0 (en) * 2023-03-29 2023-05-10 Atrogi Ab New compounds and medical uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2943090A (en) * 1957-09-23 1960-06-28 American Cyanamid Co Substituted piperazines and method of preparing the same
US3092636A (en) * 1959-10-21 1963-06-04 Upjohn Co Alpha-[2-(1-alkyleneimino) ethylamino]-alkanophenones and the corresponding alcohols
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
DE2115926C3 (de) * 1971-04-01 1978-05-03 C.H. Boehringer Sohn, 6507 Ingelheim 1 -(4-Hydroxy-3-dimethylaminosuIfamidophenyI)-2-aminoäthanderivate, Verfahren zu ihrer Herstellung und diese enthaltende Mittel
DE2833140A1 (de) * 1978-07-28 1980-02-07 Boehringer Sohn Ingelheim Neue n-substituierte heterocyclen
JPS6183147A (ja) * 1984-09-28 1986-04-26 Nippon Chemiphar Co Ltd 新規なアミノアルコール誘導体およびその製造法並びにそれを有効成分とするグルタミン酸遮断剤
JPH08165276A (ja) * 1994-12-14 1996-06-25 Dainippon Pharmaceut Co Ltd ２−アルキルアミノ−１−フェニルエタノール誘導体
GB9525177D0 (en) * 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
DE69717978T2 (de) * 1996-04-05 2003-10-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Paris Alpha-1 adrenergischer rezeptor antagonisten
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042679A1 (de) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts

Also Published As

Publication number Publication date
WO2004039784A1 (de) 2004-05-13
AU2003278157A1 (en) 2004-05-25
EP1558583A1 (de) 2005-08-03
JP2006508090A (ja) 2006-03-09
CA2504213A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
DE10251170A1 (de) Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2004012648A2 (de) Substituierte diarylheterocyclen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0287907A1 (de) Pyrazolo[3,4-d]pyrimidine, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
WO2007048840A1 (de) Neue beta-agonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
EP0670318A2 (de) Acetamide mit analgetischer und neuroprotektiver Wirkung
US7214698B2 (en) Beta-agonists, processes for preparing them and their use as pharmaceutical compositions
EP0483580A2 (de) 1-(2-Arylethyl)-Pyrrolidine
DE4036645A1 (de) Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung
DE69109132T2 (de) Indanderivate.
EP1176144B1 (de) Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
DE102004021779A1 (de) Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2007048841A2 (de) Neue indol-haltige beta-agonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE2319278A1 (de) Diuretisches und antihypertensives mittel
DE19904710A1 (de) Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP0210474A1 (de) Substituierte 3-Amino-sydnonimine, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE3509333A1 (de) Substituierte benzimidazolderivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
WO2007048842A1 (de) Benzimidazolderivate als beta-3 rezeptor-agonisten
EP1945304A2 (de) Imidazo-pyridin-haltige beta-agonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE60013607T2 (de) Bemzimidazolverbindungen und medikamente die diese enthalten
EP0575361B1 (de) Neue 1-aryl-4-piperazinyl-cyclohexancarbonsäurenitrile, ihre herstellung und verwendung
EP0037471B1 (de) 1-Aroyl-2-phenylamino-2-imidazoline, ihre Herstellung und diese enthaltende Arzneimittel
EP0213571A2 (de) 3-Aminomethylpyrrol-1-yl-alkylamine und diese Verbindungen enthaltende therapeutische Mittel
WO1990001479A1 (de) 4,5-dihydro-3(2h)-pyridazinone, verfarhren zu ihrer herstellung und ihre verwendung
AT336617B (de) Verfahren zur herstellung von neuen heterocyclischen verbindungen
AT339905B (de) Verfahren zur herstellung von neuen piperidinderivaten und deren salzen

Legal Events

Date Code Title Description
8141 Disposal/no request for examination